A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors

BACKGROUND: Glutamate signaling activates MAPK and PI3K/AKT pathways in tumor cells. Treatment with riluzole, a glutamate release inhibitor, has been previously shown to be safe in melanoma patients and produced biologic effects, but did not lead to radiographic responses, possibly due to poor pharm...

Descripción completa

Detalles Bibliográficos
Autores principales: Silk, Ann W., Saraiya, Biren, Groisberg, Roman, Chan, Nancy, Spencer, Kristen, Girda, Eugenia, Shih, Weichung, Palmeri, Marisa, Saunders, Tracie, Berman, Robert M., Coric, Vlad, Chen, Suzie, Zloza, Andrew, Vieth, Joshua, Mehnert, Janice M., Malhotra, Jyoti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250196/
https://www.ncbi.nlm.nih.gov/pubmed/35780243
http://dx.doi.org/10.1186/s40001-022-00732-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250196/
https://www.ncbi.nlm.nih.gov/pubmed/35780243
http://dx.doi.org/10.1186/s40001-022-00732-w

Ejemplares similares